Literature DB >> 10352447

Signal transduction pathway in human middle ear cholesteatoma.

E N Myers1, K Park, Y m Chun, D h Lee, S c Hwang.   

Abstract

Phospholipase C-gamma1 plays a central role in signal transduction, and it is important in cellular growth, differentiation, and proliferation. Human cholesteatoma in the middle ear is characterized by the presence of a keratinizing epithelium that is believed to have hyperproliferative properties. The purpose of this study is to elucidate the distribution of phospholipase C-gamma1 in cholesteatoma matrix and deep meatal skin with Western blot analysis and immunohistochemistry. In conclusion, overexpression of phospholipase C-gamma1 in cholesteatoma matrix suggests a possible derangement of enhanced growth signal transduction in keratinocytes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10352447     DOI: 10.1016/S0194-5998(99)70334-7

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  3 in total

Review 1.  Etiopathogenesis of cholesteatoma.

Authors:  Ewa Olszewska; Mathias Wagner; Manuel Bernal-Sprekelsen; Jörg Ebmeyer; Stefan Dazert; Henning Hildmann; Holger Sudhoff
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-06-27       Impact factor: 2.503

2.  Upregulation of phosphorylated HSP27, PRDX2, GRP75, GRP78 and GRP94 in acquired middle ear cholesteatoma growth.

Authors:  Kuen Yao Ho; Tai Sheng Yeh; Han Hsiang Huang; Kuo Feng Hung; Chee Yin Chai; Wan Tzu Chen; Shih Meng Tsai; Ning Chia Chang; Chen Yu Chien; Hsun Mo Wang; Yu Jen Wu
Journal:  Int J Mol Sci       Date:  2013-07-11       Impact factor: 5.923

3.  The role of inflammatory mediators in the pathogenesis of otitis media and sequelae.

Authors:  Steven K Juhn; Min-Kyo Jung; Mark D Hoffman; Brian R Drew; Diego A Preciado; Nicholas J Sausen; Timothy T K Jung; Bo Hyung Kim; Sang-Yoo Park; Jizhen Lin; Frank G Ondrey; David R Mains; Tina Huang
Journal:  Clin Exp Otorhinolaryngol       Date:  2008-09-30       Impact factor: 3.372

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.